{
    "paper_id": "79b9de8046987ccda00f034d86d599edb77bc32b",
    "metadata": {
        "title": "Characteristics of Traveler with Middle East Respiratory Syndrome, China, 2015 Technical Appendix Methods Detection of Virus in Samples",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "isolated by using standard density gradient centrifugation. An IFN-\u03b3 ELISPOT assay was performed as follows. A 96-well plate containing Immobilon-P membrane (MSIPS4510; Millipore, Billerica, MA, USA) was incubated with monoclonal antimonkey IFN-\u03b3 (CT610-10; U-Cytech, Utrecht, the Netherlands) at 4\u00b0C overnight and blocked with RPMI medium 1640 (no. 11875-093; Gibco, Grand Island, NY, USA) containing 0.05 mmol/L 2-mercaptoethanol, 1 mmol/L sodium pyruvate, 2 mmol/L Lglutamine, 10 mmol/L HEPES, and 10% fetal bovine serum (no. SH30070; HyClone, Logan, UT, USA) at 37\u00b0C for 2 h.",
            "cite_spans": [
                {
                    "start": 328,
                    "end": 360,
                    "text": "RPMI medium 1640 (no. 11875-093;",
                    "ref_id": null
                },
                {
                    "start": 361,
                    "end": 390,
                    "text": "Gibco, Grand Island, NY, USA)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "PBMCs were plated at a density of 2.5 \u00d7 10 5 cells/well. Recombinant MERS-CoV spike protein (no. 40069-V08B; Sino Biologic Inc., North Wales, PA, USA) and SARS-CoV spike S1 subunit (no. 40150-V08B1; Sino Biologic Inc.) were added to the wells at a final concentration of 10 \uf06dg/mL to stimulate PBMCs. Phosphatebuffered saline was used for mock stimulation. At 24-h poststimulation, IFN-\u03b3 was detected by using biotinylated anti-monkey IFN-\u03b3 (CT610-10; U-Cytech), and color was developed by using nitro-blue tetrazolium and 5-bromo-4-chloro-3'indolyphosphate (Pierce, Rockford, IL, USA). Spots were counted by using an ELISPOT reader (Bioreader 4000; BIOSYS, Germany), and the results were reported as number of spot-forming cells/million PBMCs.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Serum samples were heat-inactivated (56\u00b0C for 30 min) and mixed with equal volumes of two hundred 50% tissue cultures infectious doses of MERS-CoV. After 1 luciferase activity was measured by using a Microbeta Luminometer (PerkinElmer, Waltham, MA, USA). The highest serum dilution giving 90% reduction of luciferase activity was used as the antibody titer (2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Microneutralization Test"
        },
        {
            "text": "A commercially available (EUROIMMUN AG, L\u00fcbeck, Germany) MERS CoV S1 ELISA was used. In brief, serum dilutions, a calibrator, and controls were added to MERS CoV-coated plates and incubated for 30 min. Plates were washed 3 times and peroxidase labeled anti-human IgG was added and incubated for 30 min.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV S1 ELISA"
        },
        {
            "text": "Substrate solution was added and incubated for 15 min at room temperature.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV S1 ELISA"
        },
        {
            "text": "Reactions were stopped, and absorbance was measured at 450 nm using a reference wave length of 650 nm. The ratio between the extinction values of control/sample and calibrator was calculated. A ratio >0.8 was considered a positive result (3).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "MERS CoV S1 ELISA"
        },
        {
            "text": "Equal volumes of each serum dilution and 40-60 PFU of MERS CoV/24-well plate were mixed and incubated for 1 h at 37\u00b0C in an atmosphere of 5% CO2 in a humidified incubator. After incubation, virus/serum mixture was added to Vero cell monolayers in a 24-well format in duplicate. Plates were incubated for 1 h to enable absorption before overlaying with agarose. After 3 days, cells were fixed with 10% paraformaldehyde and stained. Titers are expressed as serum dilutions resulting in plaque inhibition >90%. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Plaque Reduction Neutralization Test"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Clinical parameters for a 43-year-old traveler with Middle East respiratory syndrome, China, 2015. A) Virus load. MERS-CoV, Middle East respiratory syndrome coronavirus. B) Cytokine levels and antibody titers. MIG, monokine induced by interferon-\uf067",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "IP10, interferon-inducible protein 10; IFN-\uf061, interferon-\uf061; IL-6",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "MCP-1, monocyte chemoattractant protein-1. C) T-cell response of peripheral blood mononuclear cells (PBMCs) after challenge with MERS-CoV spike protein. SARS-CoV, severe acute respiratory syndrome coronavirus",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "SFCs, spot-forming cells",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "D) Detection of antibodies against MERS-CoV by different assays",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "<jrn>1. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. American Journal of Hygiene. 1939;27:493-7.</jrn> <jrn>2. Hemida MG, Perera RA, Al Jassim RA, Kayali G, Siu LY, Wang P, et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill. 2014;19:pii: 20828. PubMed</jrn> <jrn>3. M\u00fcller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15:559-64. PubMed http://dx.doi.org/10.1016/S1473-3099(15)70090-3</jrn> Technical Appendix Figure 1. A) Timeline of clinical course of a 43-year-old traveler with Middle East respiratory syndrome, China, 2015. MERS-CoV, Middle East respiratory syndrome coronavirus. B-D) Chest radiographs on days 7, 11, and 35. Technical Appendix Figure 2. Body temperature of 43-year-old traveler with Middle East respiratory syndrome, by day of hospitalization, China, 2015.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}